Termites are one of the most menacing insects on earth that can cause great damage to your homes, wooden furniture, buildings and all your other belongings. Termites are also difficult to kill as they are strong insects. They can, however, be controlled with a few tips.

Tips to control termites

Termites can be controlled with some special tips. It is important to follow these tips for the best termite control methods

Keep away wooden furniture and accessories from the soil
Any kind of decaying trees should be got rid off
Never place wood or paper near a mound of termites and if you find any kind of termite debris, ensure that it is broken- the sooner, the better.
Also, keep your pipes clean and your homes free from damp and moisture.
Allow enough sunlight to enter your rooms
How do you know you may have the termite infestation and how to get rid of them?

The first sign of termite infestation is when you spot a thin trailing line on the floors or on the walls of the room. This would slowly increase over time. There are also times when you might find a hollow sound from your wooden furniture when tapped. A termite colony lives in mounds. If you find any mound near your place, then ensure to remove the mound as you may be the next person to invite termites to your home. If you feel that your house has been infested by termites, treat the area well with boric acid by putting it directly into the holes of the termites. The cracks and the crevices in your house can also be sealed with the help of the caulking gun. Tetracycline powder is also a good poison that may help to kill termites instantly. Termite control should be done at the very first instance if you feel that you have been infested by the same.

Gonadotropin-releasing hormone (GnRH) agonists have greater safety and efficacy profile than estrogens and anti-androgens among various therapies of achieving medical castration. Furthermore, slow-release formulations of GnRH agonists offer patients flexibility, improves quality of life, and eventually reduce cost. Most of the times, prostate cancer progresses with increasing testosterone hormone. Moreover, the production of testosterone can be stopped by surgically removing the testicles or thorough medication therapy. Triptorelin is GnRH agonists which is designed to stop the tentacles from making testosterone. This eventually reduces testosterone levels and minimizes progression of prostate cancer.

Click To Continue Reading on Triptorelin Market

Triptorelin is a decapeptide analogue of Luteinising Hormone-Releasing Hormone (LHRH, also called gonadotropin-releasing hormone [GnRH]). Triptorelin is extensively used in palliative treatment of hormone dependent advanced prostate cancer.

Moreover, according to National Institute for Health and Care Excellence (NICE), in May 2013, the licensed indications for luteinising hormone-releasing hormone (LHRH) agonist: triptorelin were extended to include two new indications for prostate cancer: first in neoadjuvant treatment before radiotherapy in high-risk localized or locally advanced disease and second in adjuvant treatment to radical prostatectomy in locally advanced disease at high risk of progression. Triptorelin is administrated intramuscularly or subcutaneously.

Furthermore, triptorelin is indicated for the treatment of pediatric patients two years of age and older with Central Precocious Puberty (CPP). In July 2017, U.S. Food and Drug Administration (FDA), approved Arbor Pharmaceuticals’: Triptodur, in pediatric patients with central precocious puberty. The approval follows a phase 3 clinical trial (Efficacy, Safety, and Pharmacokinetics [PK] of Triptorelin 6-month Formulation in Patients with Central Precocious Puberty), which examines prepubertal luteinizing hormone levels using triporelin therapy. Study demonstrated a return to pre-pubertal luteinizing hormone (LH) levels in 93% of enrolled patients, with pre-pubertal luteinizing hormone (LH) suppression maintained at 12 months by 98% of patients.

Triptorelin is further being studied to analyze effects of adjuvant hormonal therapy treatments of Tamoxifen, Letrozole and Letrozole + Zoledronate on bone loss in breast cancer patients. According to ClinicalTrials.gov, in July 2017, this study was sponsored by National Cancer Institute (NCI), Naples; and currently present in phase III clinical stage. Moreover, triptorelin market shows lucrative revenue growth in the near future, with the successful completion of this study and potential launch of new products during the forecast period.

Increasing Prevalence of Prostate Cancer among Global Population is expected to Aid in Market Growth

Incensing prevalence of prostate cancer worldwide and wide applications of triptorelin in prostate cancer treatment to limit the cancer progression by reducing the testosterone synthesized by body is expected to drive growth of triptorelin market during the forecast period.

For instance, according to the World Cancer Research Fund (WCRF) International, 2012, over 1.1 million cases of prostate cancer were recorded, accounting for around 8% of all new cancer cases worldwide. Furthermore, around 68% of prostate cancer cases were registered in the developed economies. Highest incidence of prostate cancer was reported in Oceania and North America, while lowest incidence was reported in Asia and Africa.

Moreover, according to the Cancer Research U.K., in 2015, around 47,151 new cases of prostate cancer were registered in the U.K. Furthermore, prostate cancer accounted for 13% of the total cancer cases in the U.K., in 2015. Prostate cancer is the second-most common cause of cancer deaths among males in the U.K. in 2014, accounting for 13% of all cancer deaths among males. In addition, according to the same source, in 2014, around 11,287 prostate cancer deaths were recorded among males in the U.K. The crude mortality rate shows that there were 36 prostate cancer deaths for every 100,000 males in the country.

Hyperphosphatemia is a condition caused due to high level of phosphate or phosphorous in the blood. Phosphate is a chemical found in body and contain mineral called phosphorous. Phosphorus mineral is very important for the development of teeth and bones and also convert food into energy for body. Phosphate is mainly found in the teeth, bones, inside the cells, and in very smaller amounts in the blood. Kidney functions for the management of phosphate level in the body. However, various complications/diseases results into impairment of kidney, which leads to chronically high level of phosphate in blood.

Click To Continue Reading on Hyperphosphatemia Drugs Market

Hyperphosphatemia is very common in people with chronic kidney disease more often in people with end-stage kidney disease. Some other possible causes of hyperphosphatemia includes diabetic ketoacidosis, uncontrolled diabetes, high vitamin D levels, and low parathyroid hormone levels.

For instance, in 2016, Astellas Pharma Inc. received marketing approval for its Kiklin Granules 86.2%, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease in Japan. In 2015, Keryx Biopharmaceuticals, Inc. received approval from European Commission for new drug Fexeric (R) (ferric citrate coordination complex), indicated for the treatment of hyperphosphatemia in adults with chronic kidney disease. In 2014, Keryx Biopharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for drug Ferric Citrate (formerly known as Zerenex), a new, oral iron-based treatment for dialysis patients with hyperphosphatemia. In 2014, Keryx Biopharmaceuticals, Inc. launched its new drug Auryxia (ferric citrate) tablets. Auryxia is an absorbable iron-based phosphate binder indicated for the treatment of hyperphosphatemia in chronic kidney disease

Strategic merger and acquisition by key players in the market is also expected to create a lucrative environment for the hyperphosphatemia drugs market growth. For instance, in 2013, OPKO Health, Inc. acquired Canada-based Cytochroma Inc., with this strategic acquisition OPKO Health, Inc. has expanded its portfolio with Cytochroma Inc.’s Alpharen, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients.

Furthermore, risk of developing hyperphosphatemia is very high in the people suffering from chronic kidney disease. Hence, increasing prevalence of chronic kidney disease is expected to increase the chances of hyperphosphatemia among population, which in turn is expected to increase demand for hyperphosphatemia drugs and drive hyperphosphatemia drugs market growth. For instance, according to the data published in National Chronic Kidney Disease Fact Sheet 2017, an estimated 30 million people or 15% of U.S. adults are suffering from chronic kidney disease. Chronic kidney diseases were estimated to be more common in Women (16%) as compared to men (13%).

Furthermore, Asia Pacific hyperphosphatemia drugs market is expected to witness significant growth in near future owing to increasing approval of novel hyperphosphatemia treatment drug in key regions such as China, and Japan. For instance, in 2014, Japan Tobacco Inc. and its subsidiary Torii Pharmaceutical Co., Ltd. received manufacturing and marketing approval of Riona Tablets 250 mg from Japanese Ministry of Health, Labor and Welfare. Riona tablet is indicated for treatment of hyperphosphatemia, it is a new phosphate binder containing ferric citrate hydrate as the active pharmaceutical ingredient.

Petri dish also called as cell culture dishes is common glassware used in research and academic laboratories and hospital in order to hold, transfer, and incubate the sample substance under study. Glass petri dish has lid over it and it majorly used to hold the culture medium of Agar on which bacteria, fungus, and virus are grown, which can be studied for various purpose. Petri dish prevents culturing microorganisms while separating them from airborne contaminates. Petri dish is significant Labware in almost all research efforts, in addition many infectious disease are diagnosed with culture medium method that utilizes petri dish. Majorly glass petri dish are used for various experimental activities. However, polystyrene plastic petri dish are also used according to sample need, as some samples are incompatible or react with glass material.

Click To Continue Reading on Petri Dish Market

Increasing research and development in the field of proteomics and genomics and high prevalence of infectious disease and cancer are the major factors driving growth of the petri dish market. For instance, According to report by the International Federation of Pharmaceutical Manufacturer and Association report published in 2017, pharmaceutical industry invests US$ 149.8 billion on research and development annually. There are more than 7000 compounds in preclinical stage of development as per same source.

High prevalence of infectious disease urinary tract infection, Tuberculosis (TB), Ebola, Sexually Transmitted Disease, and respiratory disease worldwide are expected to drive petri dish market growth. According to World Health Organization (WHO) factsheet in February 2018, in 2016, around 10.4 million people suffered from TB and 1.7 million died from the disease (including 0.4 million among people with HIV). According to same source, Over 95% of TB deaths were reported in low- and middle-income economies. Petri dish based culture medium test are carried out to confirm the presence of disease, which is expected to drive petri dish market growth.

Furthermore, according to 2012, EU Industrial R&D Investment Scoreboard, the pharmaceutical and biotechnology sectors represented 17.7% of business R&D expenditure in the world. Petri dish market is an essential part of any research efforts, which is expected to witness major traction due to increasing research activities by commercial companies and research institutes.

However, Petri dish market is been in mature stage for long with less of innovation and no new introduction from key players. Non culture based diagnostic test are rapidly emerging in the market, which offer fast and reliable results as compared to culture based test that rely on petri dish, which in turn is expected to restrain growth of the market. Furthermore, adoption of the automated liquid handling system and other lab automation tools by large research laboratories may hinder growth of the petri dish market. Various small scale manufacturers in emerging economies create strong competition in petri dish market and also makes petri dish market fragmented.

There is high prevalence of chronic disease such as cancer, cardio vascular disease, and diabetes worldwide, research efforts in developed region has been diverted to personalized medicine to cure this disease. Petri dish market would be supported due to this efforts in finding effective treatment avenues for this disease. Personalized medicine use tools of genomics, proteomics, and cell-based therapies to effectively target disease resulting in greater chance of survival of patient. Petri dish is essential part of most of this process such as cell isolation and cell culture growth. Well established healthcare infrastructure coupled with high adoption rate of new technology for the treatment of cancer in the developed region is expected to boost overall sales of petri dish in regions such as North America and Europe. There are over 200 companies engaged in development of personalized cell therapy products in the U.S. alone

In 2017, the FDA approved 2 CAR-T cell therapy for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia and adult patients with certain types of large B-cell lymphoma. Such advancement in cell-based therapy needs extensive utilization of petri dish, which is expected to fuel petri dish market growth.